Zhixiang Jintai (688443.SH) announced that today, the company received the "Pharmaceutical Registration Certificate" approved and issued by the State Drug Administration, approving the listing of the class 1 new drug Sileqi Monoclonal Antibody Injection (trade name: Jinglixi) developed independently by the company for the treatment of moderate to severe plaque psoriasis indications.
According to the announcement of Zhixiang Jintai (688443.SH) on the Smart Finance app, today, the company received the "Pharmaceutical Registration Certificate" approved and issued by the State Drug Administration, approving the listing of the class 1 new drug Sileqi Monoclonal Antibody Injection (trade name: Jinglixi) developed independently by the company for the treatment of moderate to severe plaque psoriasis indications.
It is reported that Sileqi Monoclonal Antibody Injection is the company's first product approved for listing and is expected to have a positive impact on the company's business performance.